Moreover, a recent study showed that targeting IL-17A could effectively modulate the activity of these cytokines and significantly influence the expression of molecules elevated in SSc patients at high risk for pulmonary arterial hypertension (PAH) [15]. The gene discussed is IL17A; the disease is systemic sclerosis.